CapsoVision (NASDAQ:CV) Upgraded to “Hold” at Zacks Research

CapsoVision (NASDAQ:CV) was upgraded by research analysts at Zacks Research to a “hold” rating in a research report issued on Wednesday,Zacks.com reports.

CV has been the topic of a number of other research reports. Roth Capital set a $7.00 price objective on shares of CapsoVision in a report on Tuesday. Benchmark began coverage on shares of CapsoVision in a report on Monday, July 28th. They issued a “speculative buy” rating and a $5.00 target price for the company. Weiss Ratings reiterated a “sell (e-)” rating on shares of CapsoVision in a research note on Wednesday, October 8th. Finally, Wall Street Zen raised shares of CapsoVision to a “hold” rating in a research report on Sunday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, CapsoVision presently has an average rating of “Moderate Buy” and a consensus target price of $6.00.

CapsoVision Stock Down 0.6%

NASDAQ:CV opened at $4.80 on Wednesday. CapsoVision has a 1 year low of $3.43 and a 1 year high of $5.72. The business’s 50-day simple moving average is $4.48.

CapsoVision (NASDAQ:CV) last issued its earnings results on Thursday, August 14th. The company reported ($2.02) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($1.91). The firm had revenue of $3.32 million during the quarter, compared to analyst estimates of $3.20 million.

Institutional Trading of CapsoVision

A hedge fund recently bought a new stake in CapsoVision stock. New York State Common Retirement Fund acquired a new stake in CapsoVision, Inc. (NASDAQ:CV) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 7,114 shares of the company’s stock, valued at approximately $34,000.

CapsoVision Company Profile

We are a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in our capsule endoscopy solutions to identify abnormalities of the gastrointestinal (“GI”) tract for diagnostic and screening purposes. We developed our first capsule endoscope system, currently comprising the CapsoCam Plus single-usecapsule and the CapsoCloud and CapsoView software, to panoramically visualize the small-bowel mucosa to investigate abnormalities such as obscure GI bleeding and Crohn’s disease.